Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Croconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.85 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.85 |
| ▸ | CNR1 | P21554 | 1/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.85 |
| ▸ | HTR2A | P28223 | 1/20 | 0.85 |
| ▸ | HTR2C | P28335 | 1/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.85 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Croconazole SCHEMBL1274172 | 0.99 | NR1I2 (0.86) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL36790 | 0.93 | NR1I2 (0.98) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL34369 | 0.92 | NR1I2 (1.00) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL7601955 | 0.92 | NR1I2 (1.00) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL29378466 | 0.92 | NR1I2 (1.00) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| Croconazole SCHEMBL121863 | 0.91 | NR1I2 (0.98) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL11090539 | 0.81 | NR1I2 (0.78) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL2449293 | 0.78 | HTR1A (0.73) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL2449294 | 0.78 | HTR1A (0.73) | NR1I2NR3C1HTR1AADORA3CNR1 | |
| SCHEMBL9662402 | 0.77 | NR1I2 (0.72) | NR1I2NR3C1HTR1AADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507545-B2 | Cytotoxic T cell activator comprising EP4 agonist | NATIONAL UNIVERSITY CORPORATION, HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20100216689-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2147672-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | Nat. University Corp. Hamamatsu University School of Medicine (JP) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216689-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | CD4, PTGER4, LTB4R | NR1I2 1944/4885NR3C1 841/4885HTR1A 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.